Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses

被引:8
|
作者
Campione, Elena [1 ]
Rivieccio, Antonia [1 ]
Shumak, Ruslana Gaeta [1 ]
Costanza, Gaetana [2 ]
Cosio, Terenzio [1 ,2 ]
Lambiase, Sara [1 ]
Garofalo, Virginia [1 ]
Artosi, Fabio [1 ]
Lozzi, Flavia [1 ]
Freni, Claudia [3 ]
Romeo, Alice [3 ]
Dika, Emi [4 ]
Falconi, Mattia [3 ]
Bianchi, Luca [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Dermatol Unit, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy
[3] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy
[4] Univ Bologna, Oncol Dermatol Unit, IRCCS Azienda Osped Univ Bologna, DIMEC, I-40126 Bologna, Italy
关键词
tirbanibulin; actinic keratosis; field of cancerization; SQUAMOUS-CELL CARCINOMA; PIROXICAM; 0.8-PERCENT; IMMUNE-RESPONSE; SKIN; GUIDELINES; MANAGEMENT; INSIGHTS; CARE;
D O I
10.3390/ph16121686
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: We conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm2 area for 5 consecutive days on 30 participants with AKs on the face or scalp. They were followed for at least 57 days to assess the safety profile and efficacy of the drug as well as treatment satisfaction. We evaluated six signs of local skin reaction (LSR): erythema, scaling, crusting, swelling, blisters/pustules, and erosions/ulcerations, grading the severity as mild, moderate, or severe. The effectiveness was evaluated both clinically and dermoscopically. The treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Results: On day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously. Conclusion: Tirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022
    Pellacani, G.
    Schlesinger, T.
    Bhatia, N.
    Berman, B.
    Lebwohl, M.
    Cohen, J. L.
    Patel, G. K.
    Kunstfeld, R.
    Hadshiew, I.
    Lear, J. T.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 : 3 - 15
  • [12] Tirbanibulin in actinic keratosis treatment: evaluation of effectiveness, safety and patients' satisfaction in a comparison with cryotherapy
    Pertici, Ilaria
    Fidanzi, Cristian
    Bevilacqua, Matteo
    Mori, Nicolo
    Janowska, Agata
    Romanelli, Marco
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2025, 23 (03): : 389 - 389
  • [13] Tirbanibulin 1% Ointment Effectiveness for Actinic Keratosis Treatment Evaluated by Dynamic Optical Coherence Tomography
    Cantisani, C.
    Musolff, N.
    Azzella, G.
    Gargano, L.
    Di Guardo, A.
    Longo, C.
    Guida, S.
    Rossi, G.
    Rovaldi, E.
    Rega, F.
    Grifoni, G. Cocci
    Kiss, N.
    Ambrosio, L.
    Pellacani, G.
    DERMATOLOGIC THERAPY, 2024, 2024
  • [14] Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses
    Caperton, Caroline
    Berman, Brian
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2011, 4 : 35 - 40
  • [15] SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES
    Walczak, J.
    Nogas, G.
    Chmiel, M.
    Kowalska, M.
    VALUE IN HEALTH, 2009, 12 (07) : A452 - A453
  • [16] Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study
    Bhatia, Neal
    Lain, Edward
    Jarell, Abel
    Dubois, Janet
    Tamarit, Maria Luisa
    Falques, Meritxell
    Kiyasova, Vera
    Padulles, Laura
    Otero, Raquel
    Blauvelt, Andrew
    JAAD INTERNATIONAL, 2024, 17 : 6 - 14
  • [17] Early efficacy of tirbanibulin 1% ointment in actinic keratosis with good tolerability and sustained clearance: pooled phase III results
    Gupta, Girish
    Padulles, Laura
    Hernandez, Francisco
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 77 - 77
  • [18] FAVORABLE SAFETY PROFILE OF TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES
    Du Jardin, Kristian Gaarn
    Schlesinger, Todd
    Bhatia, Neal
    Berman, Brian
    Padulles, Laura
    Cutler, David
    Lebwohl, Mark
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 30 - 30
  • [19] AI-based and LC-OCT-guided follow-up of actinic keratoses under treatment with tirbanibulin 1%
    Thamm, Janis Raphael
    Welzel, Julia
    Schuh, Sandra
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (01) : e35 - e38
  • [20] The efficacy and safety of topical 5% 5-Fluorouracil in renal transplant recipients for the treatment of actinic keratoses
    Ingham, A. I.
    Weightman, W.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2013, 54 : 13 - 13